Why the study?
Do newer antiplatelet agents (prasugrel, ticagrelor) improve outcomes compared to clopidogrel in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes (ACS)
Comparison
Newer antiplatelet agents as part of dual… vs Clopidogrel
Design
Review
Authors
Loading...
May favor prasugrel or ticagrelor over clopidogrel in ACS; leaves open optimal patient selection and bleeding mitigation.
Do newer antiplatelet agents (prasugrel, ticagrelor) improve outcomes compared to clopidogrel in patients with acute coronary syndromes?
Prasugrel and ticagrelor provide superior efficacy compared to clopidogrel in patients with acute coronary syndromes, leading to their incorporation into international guidelines despite an increased bleeding risk.
Höchtl et al. (2012) studied this question.